NCT07246863 2026-04-21
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
CatalYm GmbH
Phase 2 Recruiting
CatalYm GmbH
CStone Pharmaceuticals
Nanjing Leads Biolabs Co.,Ltd
HC Biopharma Inc.
AskGene Pharma, Inc.
Fate Therapeutics
LaNova Medicines Limited
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.